Daunotec Injection
Daunorubicin
20mg
Cipla Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 645.15 NPR |
Indications
Daunotec Injection is used for:
Acute leukaemia, AIDS-related Kaposi's sarcoma
Adult Dose
Acute Nonlymphocytic Leukemia
In combination with cytarabine 100 mg/m²/day IV for 7 days first course, for 5 days subsequent courses
<60 years old: 45 mg/m² IVP days 1, 2, 3 first course; days 1, 2 subsequent courses
>60 years old: 30 mg/m² IVP days 1, 2, 3 first course; days 1, 2 subsequent courses
Acute Lymphocytic Leukemia
45 mg/m² IVP days 1, 2, 3
Hepatic Impairment
< 1.2 mg/dL serum bilirubin: Dose adjustment not necessary
1.2-3 mg/dL serum bilirubin: 75% of regular dose
> 3 mg/dL serum bilirubin: 50% of regular dose
Child Dose
Acute Nonlymphocytic Leukemia
<2 years old or <0.5 m² BSA: 1 mg/kg IVP qWeek
>2 years old or >0.5 m² BSA: 25 mg/m² IVP qWeek
Acute Lymphocytic Leukemia
<2 years old or <0.5 m² BSA: 1 mg/kg IVP qWeek
>2 years old or >0.5 m² BSA: 25 mg/m² IVP qWeek
Renal Dose
Renal Impairment
>3 mg/dL serum creatinine: Administer 50% regular dose
Administration
IV Preparation
Reconstitute 20 mg vial with 4 mL SWI to a final concentration of 5 mg/mL
IV Administration
Vesicant, never administer IM or SC
IVP: desired dose is withdrawn into a syringe containing 10-15 mL NS, then injected over 2-3 min into the tubing or sidearm of a freely flowing IV infusion of NS or D5W
Has also been diluted in 100 mL of D5W or NS & infused over 30-45 min
Flush with 5-10 mL of IV solution before & after drug administration
Contra Indications
Heart failure. Pregnancy, lactation.
Precautions
Regular blood count and ECG monitoring; elderly, children. Hepatic or renal impairment may increase risk of toxicity. Pre-existing cardiac disease and previous treatment with doxorubicin. Myocardial toxicity leading to potentially fatal congestive heart failure may occur during therapy or mth to yr after therapy cessation. Incidence of myocardial toxicity increases after total cumulative dose exceeds 400-550 mg/m2 in adults, 300 mg/m2 in children >2 yr, or 10 mg/kg in children <2 yr. Risk of severe myelosuppression leading to infection or haemorrhage.
Lactation: excretion in milk unknown/not recommended
Pregnancy-Lactation
Interactions
Increased risk of cardiotoxicity when used with cyclophosphamide. Increased risk of hepatic toxicity when used with hepatotoxic drugs e.g. high-dose methotrexate.
Potentially Fatal: Immunisation with live vaccines is not recommended. Concurrent radiation may lead to increased radiation reaction.
Adverse Effects
Side effects of Daunorubicin :
>10%
Nausea,Vomiting,Arrhythmias,Discoloration of urine,Alopecia
1-10%
Injection site skin flare,Hyperuricemia,GI ulceration,Diarrhea
<1%
Arrythmia,Cardiomyopathy,Bilirubin increased,Pruritus,Urticaria
Frequency Not Defined
Fever,CHF,Flushing,Stomatitis,Myelosuppression,Rash,Hyperpigmentation of previously radiated areas,Transverse pigmentation of fingernails and toenails,Fertility impairment
Potentially Fatal: Bone marrow suppression, cardiac toxicity, cardiomyopathy and congestive heart failure.
Mechanism of Action
Daunorubicin forms a stable complex with DNA and interferes with the nucleic acid synthesis. It is a cell-cycle nonspecific agent, but its cytotoxic effects are mostly marked in the S-phase. It also has immunosuppressant and antibacterial effects.
Note
Daunotec 20mg Injection manufactured by Cipla Ltd.. Its generic name is Daunorubicin. Daunotec is availble in Nepal.
Farmaco Nepal drug index information on Daunotec Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.